All In MedTech

Device Trial Radar · NCT05202119

Empower: tDCS for Major Depressive Disorder at Home

Empower: Transcranial Direct Current Stimulation in Major Depressive Disorder: a Double-blind, Placebo-controlled, Randomized, Superiority Trial

Last checked: Nov 20, 2026Latest source record: Apr 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 174 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

174

Actual

Start

May 12, 2022

Primary completion

Jun 6, 2023

Study completion Aug 31, 2023

Sponsor

Lead sponsor
Flow Neuroscience ABNot on our public-company list
Sponsor type
Industry
Collaborators
University of Texas; University of East London
First posted
Jan 21, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A two-center trial to investigate whether or not active stimulation with the Flow FL-100 tDCS device is superior to sham stimulation for the treatment of major depressive disorder when used at home. Participants perform up to 36 tDCS sessions by themselves without supervision during a blinded 10-week phase, and then 30 more sessions during an unblinded open-label phase.

Conditions

  • Major Depressive Disorder

Interventions

  • Transcranial direct current stimulationDevice

    Transcranial direct current stimulation (tDCS) a non-invasive brain stimulation technique where a weak direct current (2 mA) is applied on the scalp through electrodes. The current modulates the underlying neural activity. The sessions are 30 minutes, 3-5 time a week.

  • Sham Transcranial direct current stimulationDevice

    To blind the participants of the stimulation, a standardized sham protocol is used where the current ramped up and then down breifly in the beginning and end of each session to simulate active stimulation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HDRS-17 - Hamilton Depression Ratin ScaleTime frame: 10 weeks

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • UT Health Science Center

    Houston, Texas

1 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.